https://www.selleckchem.com/products/xst-14.html
Grade 3 or worse adverse events included neutropenia (70%), hypertension (20%), and febrile neutropenia (10%). No treatment-related death was observed in any cycle. The overall response rate was 70%. The RP2D of FOLFOXIRI plus ramucirumab was determined to be 8mg/kg of ramucirumab, 165mg/m of irinotecan, 85mg/m of oxaliplatin, 200mg/m of l-leucovorin, and 3200mg/m of fluorouracil. UMIN000023277. UMIN000023277. Photodynamic therapy (PDT) schedules are based on sensitiser dose, light dose, and drug-light interval. The aim of the phase Ι st
Like
Comment
Share
